Tempus AI IPO'd at ~$8B in June 2024 from River North, and that is the AI-native shape of Illinois healthtech — on top of a $135B+ healthcare GDP floor with AbbVie, Abbott, Walgreens, and the AMA inside one state.

PAA

People also ask

• What is Tempus AI and how does it set the IL healthtech reference pattern?

  Tempus AI (Chicago HQ, NASDAQ:TEM, founded 2015 by Eric Lefkofsky) IPO'd June 2024 at ~$8B market cap on ~$700M revenue — the canonical Illinois-resident AI-native healthtech. Tempus has one of the largest clinical-genomic datasets in US oncology and ships Tempus One as the clinician-facing AI assistant. Pharma partnerships announced with AstraZeneca ($200M), Pfizer ($200M), GSK. Areza's role: AI Search visibility for Tempus-pattern firms scaling clinical + BD + recruitment surfaces — and integration support for IL-resident hospitals deploying Tempus One or competing clinical-LLM platforms. We do not compete with Tempus on oncology AI.

• Does BIPA voiceprint exposure apply to patient-facing Voice Agents in Illinois?

  Yes. Illinois healthcare organisations have settled BIPA class actions over employee-fingerprint timekeeping systems and over voice-biometric patient phone authentication. Statutory damages are $1,000 per negligent violation and $5,000 per intentional violation per individual — a typical class action involves thousands to tens of thousands of class members. Areza bakes pre-call disclosure of recording, recorded consent capture, and no voiceprint retention beyond the consented session into every IL healthtech Voice Agent deployment before launch. Audit-log retention is compliant with potential class-action discovery.

• How does GIPA intersect with Tempus-pattern oncology AI and pharma clinical-trial recruitment?

  The Illinois Genetic Information Privacy Act (410 ILCS 513) regulates disclosure and use of genetic information by employers, insurers, and healthcare entities. GIPA carries a private right of action with material recovery in some settled cases (~$100K+ per violation). Material exposure for Tempus-pattern firms handling clinical + genomic data, for AbbVie + Abbott + Astellas clinical-trial recruitment workflows screening on genetic markers, and for any AI-driven patient-recommendation engine referencing genetic information. Areza documents GIPA-aligned consent capture at engagement start for any IL deployment touching genetic information directly or indirectly.

• Is Epic the table-stakes integration for Chicago academic medical centers?

  Yes. Northwestern Medicine, UChicago Medicine, Rush, Advocate Health, and Endeavor Health all run Epic — the Chicago AMC tier is Epic-dominated. Epic Cosmos is the ~250M-patient research dataset; Auto-charting, Slicer/Dicer, and Epic AI increasingly handle ambient documentation, clinical decision support, and inbox triage. Epic-anchored health systems vet vendors against Epic interoperability (FHIR, Care Everywhere) before any AI conversation starts. Areza integrates around Epic via FHIR — Voice Agent intake books into Epic, Knowledge Bot reads from Epic-derived data under controlled access. We do not rebuild EHR functionality.

• When does FDA 21 CFR Part 11 apply to an IL pharma medical-affairs deployment?

  21 CFR Part 11 governs electronic records + electronic signatures for FDA-regulated products — applies to AbbVie + Abbott + Astellas clinical-trial systems and to any AI-generated content artefact requiring signed consent or eligibility-screening (Tempus-pattern clinical-trial workflows). Required: audit-log retention aligned to FDA recordkeeping, electronic-signature workflows aligned to 21 CFR 11.50 + 11.70, validation evidence aligned to 21 CFR 11.10. FDA Promotional Labelling Regulation (21 CFR 202.1) governs HCP-facing fair-balance with MLR (Medical-Legal-Review) pre-approval required for every consumer-surface artefact.

Frequently asked

• How do you handle HIPAA + BIPA + GIPA + Illinois Mental Health Confidentiality Act for AI surfaces at an Illinois health system or pharma?

  All four are binding constraints and we treat them as the starting point, not an afterthought. HIPAA: PHI is not used to train any model we or our sub-processors operate, data is encrypted at rest and in transit, access is audit-logged, sub-processors are listed and approved, BAA executed before any production rollout, SOC 2 Type II report attached at proposal stage. BIPA: pre-call disclosure of recording on every Voice Agent surface, recorded consent capture, no voiceprint retention beyond the consented session, audit-log retention compliant with potential class-action discovery. GIPA: explicit consent capture for any surface touching genetic information directly or indirectly (Tempus-pattern oncology AI, pharma clinical-trial recruitment on genetic markers, AI-driven recommendations referencing family history). Illinois Mental Health Confidentiality Act (740 ILCS 110): narrower data-capture scope on mental-health-affected encounters, extra-care escalation paths, audit-log retention aligned to the Act's stricter-than-HIPAA standards. We route documentation through the system's Chief Privacy Officer + CISO + outside counsel at engagement start.

• Do you integrate with Epic Cosmos + Slicer/Dicer + Auto-charting and the ambient AI scribe layer (Nuance DAX, Abridge, Suki, Augmedix)?

  Yes. Epic dominates the Chicago AMC tier (Northwestern, UChicago, Rush, Advocate, Endeavor all on Epic) and we integrate around Epic rather than competing with it. Voice Agent intake books appointments into Epic via Care Companion / EpicCare Link FHIR. Knowledge Bot reads Epic-derived data under controlled access where the system's Chief Privacy Officer approves the read scope. Where the system has Nuance DAX or Abridge live for physician ambient documentation, our Voice Agent integrates downstream for patient-facing intake and referral capture — we do not rebuild ambient scribe functionality. We integrate above the existing AI stack rather than replacing it.

• How do you handle BIPA voiceprint exposure on a patient-facing Voice Agent at an Illinois clinic or hospital?

  Every Illinois healthtech Voice Agent deployment starts with the BIPA consent architecture configured before any patient surface goes live. The flow: pre-call disclosure of recording (`this call may be recorded and analysed for service-quality and compliance with the Illinois Biometric Information Privacy Act; you may opt out at any time`), recorded consent capture in the audit log, no voiceprint retention beyond the consented session, audit-log retention compliant with potential class-action discovery. Statutory damages are $1,000 per negligent violation and $5,000 per intentional violation per individual, with private right of action. Illinois healthcare organisations have settled BIPA class actions over employee-fingerprint timekeeping and over voice-biometric patient phone authentication — we bake the consent flow into the deployment so the organisation does not become the next defendant.

• Can you sell into a Chicago Big Pharma medical-affairs team without going through firm-global procurement?

  No. The Chicago Medical Director or VP Digital Health can champion, can co-design the pilot, can get the engagement onto the firm-global vendor management queue — but cannot sign the contract. Procurement and vendor management at AbbVie + Abbott + Astellas run through firm-global teams in NYC + Lake Forest + Northbrook hubs, and global infosec + privacy + brand teams must sign off before IL-resident division commit. Our Big Pharma engagement design accepts this reality: 90-day IL-resident pilot with firm-global documentation pack ready at day 1, firm-global procurement gate at day 60, firm-global production rollout at day 120 contingent on firm-global commit. FDA 21 CFR 202.1 promotional labelling fair-balance and MLR review apply to every consumer-surface artefact, with registered Medical Director sign-off baked into the publish workflow.

• How do you handle Tempus-pattern AI-native oncology firms specifically — clinical + molecular data, pharma partnership BD, clinical-trial recruitment?

  Tempus-pattern AI-native oncology firms have a different procurement shape than AMC or pharma: faster cycles (30–90 days), Founder/CEO + CMO + CTO triad rather than committee, IPO-readiness internal controls timeline meaning every consumer-surface artefact passes Chief Compliance Officer + outside-counsel review. We engage with the editorial discipline of peer-reviewed scientific register on the AI Search citation surface (scientific-platform tone, not commercial-marketing tone), GIPA-aligned consent capture on every clinical + molecular data adjacent surface, 21 CFR Part 11 electronic-records compliance on any signed consent or eligibility-screening artefact in the clinical-trials workflow, ClinicalTrials.gov submission tracking inside Workflow Ops, BAA + DUA execution at engagement start. The AI Search citation surface for `oncology AI startup Chicago`, `precision oncology data Chicago`, `cancer LLM Chicago`, `clinical trial AI recruitment` is where the firm captures pharma BD inbound and oncologist referral inbound that would otherwise hit Tempus directly.

• How do you handle Illinois state tax (4.95%), the Chicago city personal-property-lease tax (9.0%), and the Sunshine Act + Open Payments Act for HCP-facing surfaces?

  Illinois levies a flat 4.95% state income tax on individuals and a 9.5% combined corporate income tax. Chicago adds a personal property lease transaction tax of 9.0% on cloud-software lease transactions where the lessor or lessee is in Chicago — this catches some SaaS arrangements where the city characterises the subscription as a lease. For health-system + pharma engagements, the Chicago lease tax exposure typically falls on the system or pharma campus as customer-side; we surface the exposure at contract-pricing time. For HCP-facing pharma surfaces, the Sunshine Act + Open Payments Act report HCP-directed payments and transfers of value — our AI Search + Voice Agent + Knowledge Bot work on the medical-affairs scientific-platform surface is structured to avoid triggering payment-reportability ambiguities, with MLR review applying to every artefact under 21 CFR 202.1 fair-balance rules.

• What pricing should an Illinois hospital, Big Pharma medical-affairs team, AI-native healthtech startup, or independent practice expect?

  Foundation starts at USD $5,200 for a 2–4 week conversion-first build with HIPAA + BIPA + GIPA + Illinois Mental Health Confidentiality Act-aligned service-line + physician-bio + condition pages, schema-marked content, FAQPage markup, llms.txt configured, ADA WCAG 2.1 AA compliance. AI Search retainer starts at USD $430/month with named-target citation tracking against US News Best Hospitals, Healthgrades, NIH/NCI authoritative content, peer-reviewed evidence, and the system's chosen trade-press surface. Voice Agent for inbound patient triage + scheduling + referral capture with BIPA consent + HIPAA Minimum Necessary scope adds USD $1,400–$2,300/month. A typical Illinois mid-market practice engagement combines Foundation + AI Search + Voice Agent at USD $6,800–$9,500 setup plus USD $1,800–$3,000/month for the first six months. AMC + pharma + Tempus-pattern AI-native engagements scale beyond this range given the integration map (Epic FHIR + Veeva + Salesforce Health Cloud + Snowflake + the system's ambient scribe + firm-global vendor management for pharma + 21 CFR Part 11 compliance for AI-native) — we quote those engagements per-scope rather than from the price list.

• Are you SOC 2 Type II ready for Chicago AMC + Big Pharma procurement gates, and how do you handle 21 CFR Part 11 for clinical-trials systems?

  SOC 2 Type II report is attached to every Illinois healthtech proposal. The report covers infrastructure controls — access management, change management, encryption at rest and in transit, audit-log retention, sub-processor management, vulnerability management, incident response. For AMC engagements, we additionally map HIPAA + HITECH + IL state statutes (BIPA, GIPA, Mental Health Confidentiality Act) posture at engagement start. For pharma engagements, we map FDA 21 CFR Part 11 electronic-records-and-electronic-signatures controls — audit-log retention aligned to FDA recordkeeping requirements, electronic-signature workflows aligned to 21 CFR 11.50 + 11.70, validation evidence aligned to 21 CFR 11.10. For Tempus-pattern AI-native firms, we map the IPO-readiness internal controls timeline. Our home jurisdiction is the EU, which carries GDPR + NIS2 baseline controls complementing US healthcare-sector compliance — we surface the deltas explicitly at engagement start.